全性HECT E3联酶抑制的治疗潜力
Alexander M K Rothman1, Amir Florentin2, Florence Zink3
1University of Sheffield, Sheffield, UK; Novartis BioMedical Research (NBR), Cambridge, MA, USA.
Cell
|April 3, 2025
概括
研究人员发现了全方位素E3链酶的新型抑制剂,专门针对SMURF1中的神秘腔. 这一发现通过调节BMPR2信号提供了肺动脉高血压 (PAH) 的新治疗策略.
科学领域:
- 生物化学
- 分子生物学
- 药理学
背景情况:
- 乌比基E3链酶是有吸引力的治疗点,但它们缺乏活性位点口袋阻碍了抑制剂的发展.
- 由于其独特的催化机制,同源于E6相关蛋白C终端 (HECT) 的E3链酶具有挑战性.
- 肺动脉高血压 (PAH) 与SMURF1,一个HECT E3连接酶的水平增加有关.
研究的目的:
- 确定针对SMURF1的HECT E3链酶的新型抑制剂.
- 阐明已知抑制剂的作用机制.
- 在PAH中探索SMURF1抑制的治疗潜力.
主要方法:
- 大规模的无偏的生物化学查以确定SMURF1抑制剂.
- 结构和生化分析以确定抑制剂的结合和机制.
- 基于机器学习的HECT E6AP抑制剂选.
- 对PAH进行实验模型,以评估治疗效果.
主要成果:
- 发现了与催化部位不同的SMURF1中的密码腔.
- 抑制剂通过与糖氨酸链的α-螺旋相互作用来限制催化运动.
- 在实验中的PAH中,SMURF1抑制使BMP信号正常化,恢复了血管平衡,并逆转了病理.
- 在HECT E6AP抑制剂中证实了依赖于甘氨酸的全性活性.
结论:
- 向密码性异质位点,如甘氨酸链,是抑制HECT E3链酶的可行策略.
- 在治疗PAH方面,SMURF1抑制具有治疗潜力.
- 这种方法扩大了HECT E3连接酶和相关蛋白质的可用空间.
更多相关视频
08:45Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
Published on: July 17, 2020
6.1K
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
11.3K
相关概念视频
Allosteric Regulation
57.4K
Allosteric regulation of enzymes occurs when the binding of an effector molecule to a site that is different from the active site causes a change in the enzymatic activity. This alternate site is called an allosteric site, and an enzyme can contain more than one of these sites. Allosteric regulation can either be positive or negative, resulting in an increase or decrease in enzyme activity. Most enzymes that display allosteric regulation are metabolic enzymes involved in the degradation or...
57.4K
Allosteric Proteins-ATCase
5.6K
Binding sites linkages can regulate a protein's function. For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
5.6K
Ligand Binding and Linkage
4.7K
Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked. In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...
4.7K
Feedback Inhibition
53.5K
Biochemical reactions are occurring constantly in cells, converting starting substances to different products, usually with the help of enzymes that speed the reactions. Without enzymes, it would take far too long for most reactions to occur to be useful to the cell!
53.5K
Cooperative Allosteric Transitions
7.8K
Cooperative allosteric transitions can occur in multimeric proteins, where each subunit of the protein has its own ligand-binding site. When a ligand binds to any of these subunits, it triggers a conformational change that affects the binding sites in the other subunits; this can change the affinity of the other sites for their respective ligands. The ability of the protein to change the shape of its binding site is attributed to the presence of a mix of flexible and stable segments in the...
7.8K
Amplifying Signals via Enzymatic Cascade
8.2K
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
8.2K
